IMMUNEONCO-B (01541) has announced a significant financial transaction. On June 17, 2026, the company entered into an agreement to subscribe for a financial product from Vital Ventures, with a total value of HK$87.5 million. This subscription, known as the Vital Subscription Product, will be funded entirely from the group's existing internal cash reserves and surplus funds.